Acuta Capital Partners’s Inhibrx INBX Stock Holding History

Acuta Capital Partners’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,377	Closed	-$1.29M	–	30
2025 Q4	$1.29M	Hold	16,377	–	–	0.88%	19
2025 Q3	$552K	Buy	+16,377	New	+$403K	0.57%	23

Other funds holding INBX

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Acuta Capital Partners's INBX Position: Q1 2026 in Review

Acuta Capital Partners sold out of Inhibrx (INBX) in Q1 2026, closing a stake of 16,377 shares — an estimated $1.29M sold.

Acuta Capital Partners first reported a position in INBX in Q3 2025 and held it in 2 quarters. The position peaked at $1.29M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

Acuta Capital Partners reported no remaining Inhibrx position as of Q1 2026 after selling out during the quarter.
Acuta Capital Partners sold 16,377 Inhibrx shares in Q1 2026, an estimated $1.29M.
Acuta Capital Partners first reported a position in Inhibrx in Q3 2025 and held it in 2 quarters.
Acuta Capital Partners's Inhibrx position peaked at $1.29M in Q4 2025.
135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.